Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25344786 | 0.89 | ESR2 (0.46) | PDE3BPDE3AESR2CYP19A1DDB1 | |
| SCHEMBL18705865 | 0.89 | ESR2 (0.46) | PDE3BPDE3AESR2CYP19A1DDB1 | |
| SCHEMBL785036 | 0.88 | ESR2 (0.59) | PDE3BPDE3AESR2CYP19A1DDB1 | |
| Ethylene SCHEMBL3230312 | 0.84 | ESR2 (0.55) | PDE3BPDE3AESR2CYP19A1DDB1 | |
| SCHEMBL568689 | 0.79 | GAA (0.63) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4878591 | 0.79 | GAA (0.63) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4864740 | 0.79 | GAA (0.63) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7564358 | 0.79 | MAPT (0.63) | PDE3BPDE3ACYP19A1DDB1CRBN | |
| SCHEMBL24924079 | 0.78 | CYP11B2 (0.56) | MAPTSMN1; SMN2LMNACYP11B2 | |
| SCHEMBL444141 | 0.76 | SRD5A1 (0.53) | ESR2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240150324-A1 | 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV | ASSEMBLY BIOSCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |
| US-11560370-B1 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560370-B1 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560370-B1 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | PDE3B 4395/4885PDE3A 4578/4885ESR2 2107/4885 |
| US-20240150324-A1 | 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV | HCCS, HAVCR2, MAVS | PDE3B 4395/4885PDE3A 4578/4885ESR2 2107/4885 |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | PDE3B 4395/4885PDE3A 4578/4885ESR2 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.